B-CELL NON HODGKIN LYMPHOMA

This early-stage study tests a new drug called CC312 in 44 adults with certain blood cancers (like lymphoma or leukemia) that have returned or stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. This is not a cure, but a…

This study is for children and young people with B-cell Non-Hodgkin lymphoma that has come back or not responded to treatment. Current treatments are harsh and only work for about 30 out of 100 children. The trial will test several new medicines, alone or with chemotherapy, to se…

This study tests a new type of CAR T-cell therapy for adults with certain blood cancers (B-cell lymphoma or leukemia) that have come back or not responded to treatment. The therapy uses specially 'metabolically fit' immune cells designed to work better. The main goals are to find…

This early-phase study tests an experimental drug called AZD0486 in people with B-cell non-Hodgkin lymphoma that has come back or not responded to other treatments. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals are to che…

This study tests a new drug called AZD4512, alone or with other cancer drugs, in adults with relapsed or refractory B-cell non-Hodgkin lymphoma (a type of blood cancer). The main goals are to find safe doses and check for side effects. About 91 participants will take part across …

This study tests a new drug called surovatamig (AZD0486) in adults with B-cell non-Hodgkin lymphoma that has come back or stopped responding to at least two prior treatments. The goal is to see if the drug can shrink or eliminate tumors. About 240 participants will receive the dr…

This early-stage study tests an experimental drug called SAR448501 in about 96 adults with B-cell non-Hodgkin lymphoma that has returned or stopped responding to at least two prior treatments. The main goal is to find the safest and most effective dose by monitoring side effects …

This study is for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to prior treatments. It tests a drug called loncastuximab tesirine combined with other anti-cancer drugs to see if the combination is safe and can shrink tumors. About 200 participants w…

This early-phase study tests a new treatment called MC10029 for people with certain blood cancers (like lymphoma or leukemia) that have returned or stopped responding to standard care. The treatment uses a patient's own immune cells, modified in a lab to better recognize and atta…

This early-stage trial tests a new drug called IKS03 in people with advanced B-cell non-Hodgkin lymphoma that has not responded to other treatments. The drug works like a guided missile, targeting a protein (CD19) on cancer cells to deliver a toxic payload. The study aims to find…

This early-phase trial tests a genetically modified virus (VSV-IFNβ-NIS) alone or with chemotherapy and immunotherapy drugs in people with blood cancers like multiple myeloma, acute myeloid leukemia, and lymphomas that have returned or not responded to treatment. The virus is des…

This study tests a new type of CAR-T cell therapy made locally for children whose B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma has come back or not responded to treatment. The therapy uses the patient's own immune cells, modified to target and kill cancer ce…

This study tests whether giving a special immune cell treatment (CD19 CAR-T) right after a stem cell transplant can help people with a hard-to-treat type of B-cell lymphoma. The trial involves 16 adults whose cancer has come back or not responded to standard treatments. The main …

This study tests whether adding the drug epcoritamab to standard chemotherapy (EPOCH-R) is safe and effective for people with aggressive B-cell non-Hodgkin lymphoma. About 18 participants will receive the combination as their first treatment. The goal is to see if the new mix can…

This early-phase study tests whether giving specially engineered immune cells (CAR T-cells) along with a vaccine can safely prevent B-cell lymphoma from coming back after a stem cell transplant. About 15 adults with aggressive or recurrent B-cell lymphoma will receive the treatme…

This early-phase study tests a new treatment made from cord blood cells that are specially trained to find and attack cancer cells in people with B-cell non-Hodgkin lymphoma that has come back or not responded to standard therapy. The main goal is to check safety and find the bes…

This study tests a new drug called AZD0486, alone or with other cancer drugs, in people with B-cell blood cancers like certain lymphomas and leukemias. The goal is to see if it is safe and helps shrink or control the cancer. About 408 adults will take part in this early-phase tri…

This early-stage trial tests a new treatment called DuoCAR20.19.22-D95 for adults with B-cell lymphoma or leukemia that has returned or not responded to standard therapy. The treatment uses a patient's own immune cells, which are modified in the lab to better recognize and attack…

This early-phase study is testing a new treatment called CT1190B CAR-T for adults with B-cell non-Hodgkin lymphoma that has returned or stopped responding to standard therapies. The treatment uses a patient's own immune cells, modified to better recognize and attack cancer cells.…

This study tests whether a geriatric assessment—a thorough check of physical function, thinking skills, and nutrition—can guide extra support to help adults aged 60 and older recover faster after CAR-T therapy for B-cell non-Hodgkin lymphoma or multiple myeloma. Participants will…

This study follows about 40 people who received Miltenyi CAR T cell therapy at least one year ago. Researchers will track side effects, overall health, and any return of cancer. The goal is to understand the long-term safety of this treatment.